DSM to further explore growth opportunities in China
Advertisement
Royal DSM N.V. announced that the contracts to establish nutrition and anti-infectives joint ventures in China with North China Pharmaceutical Group Corporation Ltd. (NCPC) are suspended. DSM will continue its search for partners in China as the company prepares for further growth in the country, which in 2008 represented 8% of DSM's net sales.
Jan Zuidam, Deputy Chairman of the DSM Managing Board, comments: "China is transforming from the world's manufacturing base into one of the world's leading economies with one of the highest growth rates. Economic prosperity and strong domestic demand, driven by a fast-rising income level combined with an increased focus on innovation, are expected to fuel economic growth in China for the coming decades. DSM is very well positioned in China and is continuously seeking opportunities to further improve its position."
In 2004 DSM announced its intention to form a strategic partnership with NCPC. Earlier this year the contracts for joint ventures in the areas of nutritional products (vitamins) and anti-infectives were signed.
DSM has been informed that, due to the recent change in the ownership of NCPC, the implementation of these contracts has been delayed and possibly cannot be effectuated within a reasonable timeframe. Although still interested in the cooperation, the contracts are suspended, while both parties are maintaining their ongoing business relationships. At the same time, DSM will look for alternative solutions for the prospective partnerships.
DSM will continue to explore other opportunities for further growth in China through strategic cooperation, also in the areas of nutritional products and anti-infectives.
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Actavis to acquire Alpharma's Human Generics business - Actavis becomes one of top 5 global generics players

Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany - "This new facility will allow us to better serve our customers and explore new chromatography techniques and applications"
Ajinomoto to Invest a Total of 15 Billion to Expand Production of Feed Grade Amino Acids and Umami Seasonings
New 'self-exploding' microcapsules could take sting out of drug delivery

Asphaltene analysis takes a giant step - Rice researchers develop accurate measure of aggregating particles that block oil production lines

Hybrid electro-biosystem upcycles carbon dioxide into energy-rich long-chain compounds - Upcycling CO₂ via electrochemical and metabolic engineering
Tiny Tubes for Biotransport - Researchers clarify cellular uptake mechanisms for carbon nanotubes
Albemarle Announces Custom Manufacturing Agreement With ExxonMobil Chemical - Agreement provides 15,000 metric tons per year of high viscosity polyalphaolefins production

Water-Soluble Warped Nanographene - Synthesis of a water-soluble warped nanographene and its application for photo-induced cell death
Great interest in million-euro idea - Covestro funds best employee start-up team
